Reuters logo
BRIEF-AstraZeneca says Bydureon EXSCEL trial demonstrated favourable cardiovascular safety profile
September 14, 2017 / 4:31 PM / 7 days ago

BRIEF-AstraZeneca says Bydureon EXSCEL trial demonstrated favourable cardiovascular safety profile

Sept 14 (Reuters) - Astrazeneca Plc:

* BYDUREON EXSCEL TRIAL DEMONSTRATES FAVOURABLE CV SAFETY PROFILE AND FEWER CV EVENTS IN PATIENTS WITH TYPE-2 DIABETES AT WIDE RANGE OF CV RISK

* EXENATIDE ONCE-WEEKLY DID NOT INCREASE INCIDENCE OF MACE COMPARED TO PLACEBO

* “THERE WERE ALSO FEWER CV EVENTS OBSERVED IN EXENATIDE ARM OF TRIAL”

* “PRIMARY EFFICACY OBJECTIVE OF A SUPERIOR REDUCTION IN MACE NARROWLY MISSED STATISTICAL SIGNIFICANCE” Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below